Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
Leiden, Netherlands (ots/PRNewswire) - Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days ...